Kovi HIPEC trial
Reading Document
Medical Text Search
KOVION HIPEC trial ovarian cancer cytoreductive surgery
Medical Text Search
hyperthermic intraperitoneal chemotherapy ovarian cancer randomized trial results
GradeResponse
GradeResponse
The in-house database doesn't have dedicated content on the Kovi trial. Drawing on my knowledge to provide a thorough answer:
KOVI HIPEC Trial
The KOVI trial (also referenced as the OVHIPEC-2 trial or related Dutch cohort work) is somewhat ambiguous in name — the most prominent Dutch-led HIPEC trial in ovarian cancer is the OVHIPEC-1 trial (van Driel et al.), and its follow-up OVHIPEC-2. If you are referring to a different "Kovi" trial, please clarify — but below is a comprehensive overview of what is most likely meant.
OVHIPEC-1 Trial (van Driel et al., NEJM 2018)
This is the landmark randomized controlled trial of HIPEC in ovarian cancer that generated the most discussion.
Design
- Full name: OVHIPEC (OVarian cancer HyPErthermia ChEmotherapy) trial
- Journal: New England Journal of Medicine, 2018
- PI: Willemien J. van Driel, Simone N. Koole, Gabe S. Sonke (Netherlands Cancer Institute)
- Phase: III RCT
- N: 245 patients
Population
- Stage III epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Eligible if residual disease ≤1 cm after neoadjuvant chemotherapy (NACT) — i.e., at interval cytoreductive surgery (ICS)
Intervention
- Arm A: Interval cytoreductive surgery (ICS) alone + adjuvant chemotherapy
- Arm B: ICS + HIPEC (cisplatin 100 mg/m², 40°C, 90 minutes) + adjuvant chemotherapy
Key Results
| Outcome | Surgery Alone | Surgery + HIPEC | HR / p-value |
|---|---|---|---|
| Median Recurrence-Free Survival | 10.7 months | 14.2 months | HR 0.66, p=0.003 |
| Median Overall Survival | 33.9 months | 45.7 months | HR 0.67, p=0.02 |
| Grade 3–4 Adverse Events | 25% | 27% | NS |
Conclusions
- HIPEC at the time of ICS significantly improved both RFS and OS without a meaningful increase in serious adverse events.
- Became widely cited as practice-changing, though controversially so.
Controversy and Criticism
Despite impressive results, OVHIPEC-1 faced significant methodological criticism:
- No blinding — surgeons and patients knew treatment allocation.
- Imbalance in residual disease — complete cytoreduction rate was higher in the HIPEC arm (62% vs. 57%), potentially confounding results.
- Carboplatin vs. cisplatin debate — different systemic chemotherapy regimens used across arms raised concerns.
- No sham surgery control — placebo effect and performance bias possible.
- Generalizability — performed at a single high-volume center.
Vergote et al. (Cancer, 2019) published a critical commentary arguing the benefit may be attributable to selection bias and incomplete cytoreduction differences rather than HIPEC itself.
OVHIPEC-2 Trial
A follow-up trial was initiated to evaluate HIPEC at primary cytoreductive surgery (rather than interval), addressing some criticisms of the first trial. Results are pending or emerging.
HIPEC Regimen Details (as used in OVHIPEC-1)
- Agent: Cisplatin
- Dose: 100 mg/m²
- Temperature: 40°C
- Duration: 90 minutes
- Carrier solution: Normal saline
- Technique: Closed abdomen technique
Current Clinical Context
- NCCN and ESMO: acknowledge HIPEC as an option at interval cytoreduction in select patients with Stage III disease, though not universally recommended due to ongoing debate.
- SOC: Several centers now offer HIPEC routinely post-OVHIPEC-1; others await further confirmatory data.
- Ongoing trials: iHIPEC, CHIPOR, and others are evaluating HIPEC in recurrent/platinum-sensitive settings.
If "Kovi HIPEC" refers to a specific investigator-named trial, a national registry study, or a trial I may not have current data on (post-2023), please share more context and I can help further.
This is a shared conversation. Sign in to Orris to start your own chat.